HSIC Henry Schein, Inc. - Common Stock

Henry Schein trades at $86.39 and has moved in lockstep with the market. Its shares have returned 18.8% over the last six months while the S&P 500 has gained 21.4%.

Henry Schein (HSIC) is back in focus after amending and restating its revolving credit facility, increasing total commitments to $1.25 billion and extending the termination date to September 19, 2031. Against that backdrop, Henry Schein’s share price has moved to $86.37, with a 1-day share price return of 0.98% and a 7-day share price return of 1.80%. The 30-day share price return declined 3.52%, and the year-to-date share price return is 12.43%. The 1-year total shareholder return of 30.74%...

Henry Schein has delivered a 30.7% share price gain over the past year, which naturally puts the spotlight on whether that move is backed by the cash the business is expected to generate. With the stock recently closing at US$86.37, the key issue now is how that price lines up against the value suggested by its cash flows. The 30.7% return over the past 12 months raises a straightforward question for holders and potential buyers: whether the cash that Henry Schein can produce is enough to...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Henry Schein (HSIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

HSIC vs. SAUHY: Which Stock Is the Better Value Option?

Henry Schein (HSIC) could produce exceptional returns because of its solid growth attributes.

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Henry Schein stock performance snapshot Henry Schein (HSIC) stock has drawn investor attention after recent share price moves, with the company reporting positive total returns over the past year and across multi year periods, alongside reported revenue and net income growth. At the latest share price of US$88.52, Henry Schein has given investors a 16.9% share price return over the past 90 days and a 29.4% total shareholder return over the past year. This suggests momentum has been building...

MD Sass, a boutique asset management firm, published its second-quarter investor update for its flagship, the “MD Sass Concentrated Value Strategy.” The letter can be downloaded here. In the first half of 2026, AI infrastructure stocks led the market, with the Russell 1000 Value increasing by 16.3%, outpacing the S&P 500 (10.2%) and Russell 1000 […]

HSIC vs. SAUHY: Which Stock Is the Better Value Option?

Henry Schein has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Henry Schein's broader growth, recurring technology revenues and savings plan support its outlook, but leverage and execution risks remain key concerns.

Henry Schein's stronger Q2 sales and margins prompt a 2026 outlook hike, but second-half savings execution remains key to sustaining earnings momentum.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Align's $37.5M U.K. VAT liability, new 20% VAT charges and pending appeal add fresh earnings uncertainty amid currency and mix pressures.

Henry Schein delivered a positive second quarter, with results exceeding Wall Street’s expectations and earning a strong market response. Management attributed the outperformance to accelerating internal sales growth, robust gains in its global dental merchandise segment, and early benefits from value creation initiatives. CEO Frederick Lowery emphasized the company’s success in converting occasional buyers into engaged customers and highlighted strong market share gains, particularly in the U.S

Cloud-based dental software drives margin expansion and record customer growth.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

HSIC vs. SAUHY: Which Stock Is the Better Value Option?

Henry Schein, Inc. reported past Q2 2026 results with sales rising to US$3,458 million and net income to US$94 million, alongside higher basic and diluted earnings per share from continuing operations versus a year earlier. Importantly for long-term watchers, management also raised its 2026 total sales growth guidance, signaling greater confidence in the company’s operating initiatives and demand trends. Now we’ll examine how Henry Schein’s raised 2026 sales outlook reshapes its existing...

Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Henry Schein stock has delivered a 37.5% return over the past year, yet the valuation picture is more mixed, with the Discounted Cash Flow (DCF) intrinsic value estimate indicating the shares may be trading at a sizeable discount while earnings based multiples look closer to fair. Henry Schein's 37.5% one year return suggests investors have already priced in a meaningful improvement in the story, so additional upside may depend on how the fundamentals evolve from here. The leadership...

Moby summary of Henry Schein, Inc.'s Q2 2026 earnings call

Henry Schein (NASDAQ:HSIC) reported higher second-quarter sales, operating margins and earnings, citing accelerating internal sales growth, market-share gains in dental merchandise and early benefits from its value-creation program. The company also raised its full-year sales and adjusted earnings g

Henry Schein tops Q2 earnings and revenue estimates as internal sales growth accelerates and management raises its 2026 outlook, lifting shares.

While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

Henry Schein (HSIC) delivered earnings and revenue surprises of +4.10% and +2.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Dental and medical products company Henry Schein (NASDAQ:HSIC) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 6.7% year on year to $3.46 billion. Its non-GAAP profit of $1.27 per share was 2.5% above analysts’ consensus estimates.

Dental and medical products company Henry Schein (NASDAQ:HSIC) will be reporting results this Tuesday before the bell. Here’s what you need to know.

The reorganization comes months after Fred Lowery was named CEO and the company deepened its relationship with private equity firm KKR.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the dental equipment & technology stocks, including Henry Schein (NASDAQ:HSIC) and its peers.

HSIC heads into Q2 earnings with expectations for revenue and EPS growth as dental, specialty products and AI-enabled technology remain in focus.

A steadily shrinking share count and a giant float owed to suppliers are handing owners a bigger slice of the drug distributor each year, even as drug-pricing worries hang over the stock.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Upcoming earnings release puts focus on Henry Schein stock Henry Schein (HSIC) is back on investors’ radar after announcing it will report second quarter 2026 results before the market opens on August 4, followed by an earnings conference call and webcast. See our latest analysis for Henry Schein. Henry Schein’s recent share price performance has been firmer over the past few months, with a 30 day share price return of 7.43% and a year to date share price return of 11.77%. Meanwhile, the 1...

Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Henry Schein will release its second-quarter earnings soon, and analysts anticipate a low double-digit bottom-line growth.